Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2022  |  Volume : 18  |  Issue : 6  |  Page : 1604-1609

Fractionated stereotactic radiotherapy as a primary or salvage treatment for large brainstem metastasis


1 Department of Radiotherapy and Oncology, University Hospital, Goethe University Frankfurt, Frankfurt; Saphir Radiosurgery Center, Frankfurt am Main, Germany
2 Saphir Radiosurgery Center, Frankfurt am Main, Germany
3 Department of Radiotherapy and Oncology, University Hospital, Goethe University Frankfurt, Frankfurt, Germany

Correspondence Address:
Georgios Chatzikonstantinou
Department of Radiotherapy and Oncology, University Hospital Frankfurt, Goethe University Frankfurt, Theodor-Stern-Kai 7, D-60590. Frankfurt amMain
Germany
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jcrt.jcrt_426_21

Rights and Permissions

Introduction: This study aimed to determine the efficacy and safety of robotic-based fractionated stereotactic radiotherapy (FSRT) in the treatment of large brainstem metastases (BSMs). Methods: Ten BSM were treated in ten patients with FSRT between January 2012 and December 2018. The median age was 61 years (range, 53–74 years) with a median Karnofsky Performance Score of 80 (range, 70–90). Four patients (40%) had received whole-brain radiotherapy prior to FSRT. The median tumor volume was 4.2 cm3 (range, 1.35–8.18 cm3) with a median prescription dose of 24 Gy (range, 16–24 Gy) delivered in 3–5 fractions (median three fractions) to the 56%–83% isodose line (median 70.5%). Results: 1Median follow-up for the entire cohort was 14.1 months (range, 4.6–19.3 months). Five local recurrences were documented. Local control (LC) rate at 6 and 12 months was 90% and 64.2%, respectively. The median tumor volume of patients developing local recurrence was 5.42 cm3. Three patients experienced intracranial out-of-field failure for a 12-month intracranial control rate of 78.7%. Median overall survival and time to extracranial progression were 14.7 and 16.8 months, respectively. Toxicity was low with only one patient developing a new hemiparesis. Conclusion: Robotic-based FSRT for BSM appears to be safe with favorable LC and low toxicity even for large tumors.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed414    
    Printed36    
    Emailed0    
    PDF Downloaded26    
    Comments [Add]    

Recommend this journal